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Rapid immune reconstitutiondparticularly of natural killer cells (NK cells)dafter allogeneic hematopoietic
stem cell transplantation (HSCT) is associated with protection from relapse. Whether such an association also
exists after autologous stem cell transplantation is less clear. We retrospectively assessed lymphocyte subsets
after autologous HSCT in 114 patients and correlated lymphocyte recovery with outcome. CD8 T cell and NK
cell counts recovered rapidly to pretransplantation levels, whereas B cell and CD4 T cell recovery were
delayed. Compared with patients with low NK cells (<100/uL), high NK cell count at 1 month after HSCT was
associated with signiﬁcantly prolonged progression-free survival: for NK cells 100 to 200/uL hazard ratio
[HR], .33 (95% conﬁdence interval [CI]; .16 to .80; P ¼ .004); for NK cells > 200/mL HR, .27 (95% CI, .13 to .58;
P ¼ .001). No signiﬁcant protective effects were associated with rapid recovery of any other lymphocyte
subset. None inﬂuenced overall survival (OS) or time to next treatment. Early NK cell recovery is associated
with better progression-free survival after autologous HSCT. The failure to detect an effect on OS might be due
to the salvage strategies available to these patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) relies on graft-versus-tumor (GVT) effects for its
curative potential. Accordingly, early recovery of donor-
derived lymphocytes has been associated with improved
survival [1-4]. In the setting of T celledepleted trans-
plantation, a protective effect has been attributed to early
reconstitution of natural killer (NK) cells, the ﬁrst lympho-
cyte subset to reconstitute after this transplantation type [5].
Whether a similar association also exists for patients who
underwent transplantationwith autologous stem cells is less
clear. Early lymphocyte reconstitution has been associated
with a favorable outcome of autologous HSCT for non-
Hodgkin lymphoma [6,7] and plasma cell myeloma [8,9].
Which lymphocyte subset is responsible for this association
has so far not been investigated.
As both autologous and allogeneic NK cells have been
shown to be able to recognize and lyse plasma cells of
myeloma patients [10,11], we hypothesized that early NK cell
recovery might be associated with autologous GVT effects
and improved disease control after autologous HSCT for
plasma cell myeloma. To address this question, we retro-
spectively analyzed lymphocyte subset (ie, CD4 T cell, CD8
T cell, NK cell, and B cell) recovery in a cohort of patients
undergoing autologous HSCT for plasma cell myeloma.edgments on page 899.
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Transplantation Procedure
We analyzed 114 patients undergoing autologous HSCT at Basel Uni-
versity Hospital between 2001 and 2011. All patients underwent autologous
HSCT after conditioning with melphalan 200 mg/m2 (140 mg/m2 in case of
renal failure). All patients were treated for plasma cell myeloma. All patients
received unmanipulated grafts. Further patient and transplantation char-
acteristics are summarized in Table 1. All patients gave written informed
consent to the transplantation procedure and to analysis of outcome data.
The study was performed according to the regulations of the local ethics
committee.Flow Cytometry
Lymphocyte subpopulations were systematically assessed before start of
the conditioning regimen, as well as 1, 3, 6, 12, and 24 months after trans-
plantation. After 2005, lymphocytes were immunolabeled using BD Trucount
beads (BD Biosciences) and BDMultitest reagents (BD Biosciences, San Jose, CA)
with an antibody combination of CD3-FITC/CD16-PE þ CD56-PE/CD45-peridin
chlorophyl protein (PerCP)/CD19-allophycocyanin (APC) and CD3-FITC/CD8-
PE/CD45-PerCP/CD4-APC, according to manufacturer’s recommendations
[12]. Sampleswere analyzed within 2 hours on a FACSCalibur (BD Biosciences).
Dot plots were analyzed using FACS Multiset software (BD Biosciences). Before
2005, lymphocyte subpopulations were assessed in whole blood by a dual-
platform, 3-stage process: (1) the white blood cell count (WBC), (2) the per-
centage of WBCs that are lymphocytes, and (3) the percentage of lymphocytes
that are T, B, or NK cells. The last stage in the process was performed by ﬂow
cytometry. Lymphocytes were hereby immunolabeled and analyzed using a
similar procedure described above for the single-platform method; however,
without BD Trucount beads.Statistics
The effect of lymphocyte reconstitution on transplantation outcomewas
analyzed in an univariate analysis by categorizing subset counts at different
time points and calculating probabilities of overall survival (OS),
progression-free survival (PFS), and time to next treatment using the
Kaplan-Meier estimator. We set our cut offs for lymphocyte subset by pa-
tient numbers to have 3 similar cohorts. Estimated survival rates were
compared by log-rank test. The correlation between lymphocyte counts and
transplantation outcome was further analyzed in multivariable Cox models
adjusting for covariates. Cox models were adjusted for disease stage, patient
age, cytogenetics, and remission status at transplantation. Response to
treatment and relapse/progression events were classiﬁed according to
consensus guidelines [13].
Table 1
Patient Characteristics
Characteristic Value
No. of patients 114
Year, median (range) 2008 (2001-2011)
Age, median (range), yr 61 (27-76)
Sex (male/female) 78/36
Types
IgG 58
IgA 29
IgM 2
IgD 1
Light chain 21
Nonsecretory 3
Cytogenetics
Normal 37
Del13.q14 22
Del13.q14 and del17 9
Del13.q14 and IgH rearrangement 6
IgH rearrangement 4
NA 36
ISS
I 34
II 45
III 10
NA 25
Durie-Salmon
I 16
II 35
III 63
Renal function
Creatinine < 2 mg/dL 88
Creatinine > 2 mg/dL 15
NA 11
Lines of treatment before treatment,
median (range), n
1 (0-5)
No. of transplantations
First 84
Not ﬁrst 30
Remission status at transplantation
sCR/CR 46
VGPR/PR 54
SD/PD 12
NA 2
Novel agents before HSCT
Yes 59
No 55
ISS indicates International Staging System; sCR, stringent complete remis-
sion; CR, complete remission; VGPR, very good partial response; PR, partial
response; SD, stable disease; PD, progressive disease; NA, not available;
HSCT, hematopoietic stem cell transplantation.
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Of the 114 patients, 85 were alive at last contact with a
median follow-up of 38 months. Median OS, PFS, and time to
next treatment were 81 months, 11 months, and 40 months,
respectively. The majority of patients had stage II or higher
disease and were in partial or better remission at the time of
transplantation (Table 1).
Mean lymphocyte counts for CD3þ/CD8þ T cells, CD3þ/
CD4þ T cells, CD3/CD56þ NK cells, and CD19þ B cells at the
time points analyzed are shown in Figure 1. CD8 Tcell and NK
cells achieved healthy donor levels at 1 month, whereas
CD4þ T cells and B cells showed delayed recovery.
Lymphocyte Subset Reconstitution and Disease Relapse
Correlation of lymphocyte subset recovery and trans-
plantation outcome revealed a signiﬁcant effect of NK cell
recovery at 1 month on PFS. Median PFS was 2.2 months for
patients with NK cell count below 100 cells/mL and
11.6 months both for patients with an NK cell count between
100 and 200 or above 200 cells/mL (P ¼ .001) (Figure 2A).
A similar difference in PFS was detected if the analysis wasrestricted to patients receiving their ﬁrst transplantation
(PFS for NK cells < 100/mL, 2.7 months; for NK cells 100 to
200/mL, 15.8 months; and for NK cells> 200/mL, 10.8 months;
P < .001). Multivariable analysis conﬁrmed the 1-month NK
cell count as an independent predictor of PFS (Table 2), along
with remission status at transplantation and cytogenetic
proﬁle. No similar associationwas detected at this time point
for numbers of CD8 T cells (PFS at 6, 16, and 11 months for 1-
month CD8 counts of < 400, 400 to 800, and > 800/mL), the
number of CD4 T cells (PFS at 10, 12, and 11 months for CD4
counts of <200, 200 to 300, and >300/mL), or the number of
B cells (PFS at 10, 9, and 12 months for B cell counts of < 10,
10 to 50, and > 50/mL).
No signiﬁcant association with PFS was detected for any
of the other time points analyzed. In contrast to PFS,1-month
NK cell count had no signiﬁcant inﬂuence on either time to
next treatment (P ¼ .93) (Figure 2B) or OS (P ¼ .52)
(Figure 2C).
DISCUSSION
The aim of our study was to analyze whether rapid
lymphocyte subset recovery after autologous HSCT in plasma
cell myeloma had an impact on outcome. The role of immune
recovery subsequent to allogeneic HSCT has been widely
analyzed. Several studies demonstrated that rapid immune
reconstitution has a signiﬁcant positive effect on outcome.
It was shown that rapid recovery of lymphocytes, measured
as absolute lymphocyte count (ALC) at different time points,
was a strong and independent positive predictive factor on
OS and PFS. Savani et al. [5] showed that high ALC on day 30
after T celledepleted allogeneic HSCT was associated with
increased survival, less relapse, lower nonrelapse mortality,
and less acute GVHD. These results were conﬁrmed in mul-
tiple studies [3,4,6,8,9,14-16]. Breaking down ALC into the
various subsets, it was observed that NK cells were the ﬁrst
lymphocytes to recover after transplantation and correlated
with ALC as a prognostic marker [17]. Having the ability to
perform direct cytotoxicity without prior sensitization, NK
cells play a signiﬁcant role in the innate immunity and in
antitumor response [18,19].
Immune reconstitution after autologous HSCT has also
recently been studied and correlated with outcome. Several
studies indicated a similar association between rapid
immune recovery and favorable outcome as in allogeneic
transplantation. Porrata et al. [15] reported that ALC at day 15
with a cut off of > 500 cells/mL had signiﬁcant association
with prolonged survival in AML postautologous HSCT.
Similar results were described in the setting of T cell non-
Hodgkin’s lymphoma using 1000 cells/mL as a discriminator
[14] within 25 days postautologous HSCT. Results showed
signiﬁcant positive effects on OS and PFS.
In plasma cell myeloma, Porrata et al. [9] were the ﬁrst to
demonstrate a positive association between high ALC on day
15 (cut off of > 500 cells/mL) and outcome. Kim et al. [8]
conﬁrmed these ﬁndings, observing ALC  1000/mm3 at
day 23 as positive prognostic factor for OS and PFS. Hiwase
et al. [20] showed similar results, using ALC at day 30 as a
prognostic cut off. Hiwase et al. analyzed additionally the
kinetics of the lymphocyte recovery, measuring ALC at day
30, 60, 100, 180, and 365. The beneﬁt on survival could only
be conﬁrmed for high ALC at day 30. This reinforces the hy-
pothesis that a fast immune recovery is essential for a
beneﬁcial effect on outcome.
To investigate which lymphocytes were responsible for
the beneﬁcial impact, we conducted a retrospective analysis
Figure 1. Reconstitution of lymphocyte subsets (CD8 T cells [CD8þ/CD3þ], CD4 T cells [CD4þ/CD3þ], natural killer cells [CD56þ/CD16þ/CD3], and B cells [CD19þ])
after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Curves represent means  standard errors of the mean, and gray areas represent
the range of healthy donor normal values.
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autologous HSCT. We assessed CD4 and CD8 T cells, B cell,
and NK cell kinetics postautologous HSCT, focusing on the
possibility of NK cellemediated a GVT-like effect in that
setting, as NK cells have been shown to lyse autologous
plasma cells of myeloma patients [10,11]. Our analysis
showed that high NK cell count at 1 month had a signiﬁcant
effect on PFS for NK cells > 100 cells/mL. This result was
conﬁrmed by multivariable analysis. Compared with priorFigure 2. Rates of progression-free survival (A), time to next antimyeloma treatment (
cell myeloma. Patients are grouped by their NK cell count at day 30 after autologousstudies, we could not ﬁnd any effect on OS. A possibility for
the lack of effect on OS might be due to the excellent salvage
therapies available. None of the other subsets analyzed had
signiﬁcant impact at any time point.
The data presented here raise the question whether fac-
tors that inﬂuence NK cell reconstitution may be modiﬁed
with the aim to delay disease relapse. Unfortunately,
although several studies have looked at alterations in NK cell
receptor expression after allogeneic HSCT [21,22], little isB), and overall survival (C) in patients treated with autologous HSCT for plasma
HSCT.
Table 2
Multivariate Analysis for PFS
Risk Factor HR 95% CI P Value
NK cell count at 1 mo
<100 cells/mL (n ¼ 12) 1 -
100-200 cells/mL (n ¼ 38) .33 .16-.70 .004
>200 cells/mL (n ¼ 50) .27 .13-.58 .001
Status at transplantation
CR/VGPR (n ¼ 38) 1 -
PR/SD/PD (n ¼ 57) 2.83 1.66-4.82 <.001
Cytogenetics
Normal (n ¼ 29) 1 -
Abnormal (n ¼ 32) 2.28 1.32-4.23 .01
HR indicates hazard ratio; CI, conﬁdence interval; NK, natural killer; CR,
complete remission; VGPR, very good partial response; PR, partial response;
SD, stable disease; PD, progressive disease, PFS, progression-free survival.
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tion, and immune recovery after autologous HSCT has, in
general, not received much attention. As NK cells recon-
stituting after HSCT are de novo produced from infused
progenitor cells, the number of CD34þ infused cells might be
an obvious predictor of NK cell recovery. However, in this
study, correlation between CD34þ infused and 1-months NK
cell count was poor (Pearson’s correlation coefﬁcient, .19;
P ¼ .08). Regarding interventions to hasten NK cell recovery,
cytokine administration after HSCT might be an option.
Interleukin-15 has been shown to increase NK cell number
and functionality in murine models of bone marrow trans-
plantation [23]. The observed increase in graft-versus-host
disease in mice treated with IL-15 should not present any
issues after autologous stem cell transplantation.
Mechanistically, the positive correlation between NK cell
count at 1 month and PFS might represent evidence for a
weak autologous GVT effect. Causality cannot be conﬁrmed,
however, in this type of study. An alternative explanation
includes better NK reconstitution related to the depth of
remission. In conclusion, our study shows that NK cell count
after 1 month has signiﬁcant impact on PFS and that a weak
NK cellemediated autologous GVT effect could be a possible
explanation.ACKNOWLEDGMENTS
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